CCDC 1982336: Experimental Crystal Structure Determination

Pei‐Pei Kung(Pfizer (United States)), Martin P. Edwards(Pfizer (United States)), Alexei Brooun(Pfizer (United States)), Wei Liu(Dalian Institute of Chemical Physics), Lisa Nguyen(Pfizer (United States)), Penney Khamphavong(Pfizer (United States)), K.S. Gajiwala(Pfizer (United States)), Luke R. Zehnder(University of Minnesota), Huichun Zhu(Pfizer (United States)), Robert S. Kania(RG Biopharma (United States)), Michael R. Collins(Pfizer (United States)), Manfred Kraus(Harvard University), Shikhar Sharma(Pfizer (United States)), Shuibo Xin(WuXi AppTec (China)), Patrick Bingham(Pfizer (United States)), Shinji Yamazaki, Shuiwang Wang(WuXi AppTec (China)), Susan E. Kephart(Pfizer (United States)), Scott C. Sutton, Robert A. Kumpf(Pfizer (United States)), Neal W. Sach(Pfizer (United States)), Jillian E. Spangler(Scripps Research Institute), Martin Wythes(Pfizer (United States)), Hovhannes J. Gukasyan(Pfizer (United States)), Karen A. Maegley(Pfizer (United States)), Wenyue Hu(Beijing University of Chinese Medicine), Dominique Verhelle(Pfizer (United States)), Sean Uryu(Pfizer (United States)), Dan Richter(Pfizer (United States)), Cody Krivacic(Pfizer (United States)), Hui Wang(Ministry of Education), JinJiang Zhu(Pfizer (United States)), Dac M. Dinh(Pfizer (United States)), Albert Stewart(Pfizer (United States)), Shijian Ren(WuXi AppTec (China)), John Sherrill(Pfizer (United States)), Robert A. Rollins(Pfizer (United States)), Rita Grantner(Pfizer (United States)), Buwen Huang(Pfizer (United States)), Connie Fan(Pfizer (United States))
The Cambridge Structural Database
February 7, 2020
10.5517/ccdc.csd.cc24jsbt
Cited by 0

Related Papers

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
|Journal of Medicinal Chemistry|2014|587
Ligand-Controlled C(sp <sup>3</sup> )–H Arylation and Olefination in Synthesis of Unnatural Chiral α–Amino Acids
|Science|2014|501
Using the Golden Triangle to optimize clearance and oral absorption
|Bioorganic & Medicinal Chemistry Letters|2009|382
Lipophilic Efficiency as an Important Metric in Drug Design
|Journal of Medicinal Chemistry|2018|340